Search for other papers by Zixia Tao in
Google Scholar
PubMed
Search for other papers by Xianzhao Deng in
Google Scholar
PubMed
Search for other papers by Bomin Guo in
Google Scholar
PubMed
Search for other papers by Zheng Ding in
Google Scholar
PubMed
Search for other papers by Youben Fan in
Google Scholar
PubMed
The incidence rate of medullary thyroid carcinoma (MTC) continues to grow, along with its mortality rate in the USA. However, the subgroup trends in MTC have not yet been established. This population-based retrospective cohort study was based on the Surveillance, Epidemiology, and End Results (SEER) 17/12 registry database. Subgroup analysis was performed through clinicopathological and treatment-related characteristics. Annual average percentage change (AAPC) was calculated using joinpoint regression analysis. A total of 3833 MTC patients and 536 death cases were diagnosed in the SEER database. Between 2000 and 2019, the incidence (AAPC = 1.64) and mortality (AAPC = 3.46) rates of MTC continued to rise. Subgroup analysis showed the proportion of elderly patients (65–84 years) gradually increased in incidence between 2000 and 2020. Patients with early-stage tumors, such as tumors ≤20 mm, showed the same trends. Aspects of treatment, the implementation rate of total thyroidectomy (AAPC = 0.38) and lymph node dissection (AAPC = 1.06) also increased persistently in almost all of the age subgroups. The incidence and mortality of MTC consistently increased from 2000 to 2019. Subgroup analysis indicated a significant increase in elderly patients and early-stage patients, and more attention should be paid to the management of these increased subgroups.
The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA
Center for Cancer Engineering, The Ohio State University, Columbus, Ohio, USA
Search for other papers by Aleksander Skardal in
Google Scholar
PubMed
Search for other papers by Hemamylammal Sivakumar in
Google Scholar
PubMed
Search for other papers by Marco A Rodriguez in
Google Scholar
PubMed
Search for other papers by Liudmila V Popova in
Google Scholar
PubMed
Center for Cancer Engineering, The Ohio State University, Columbus, Ohio, USA
Division of Surgical Oncology, The Ohio State University and Arthur G. James Comprehensive Cancer Center, Columbus, Ohio, USA
Search for other papers by Priya H Dedhia in
Google Scholar
PubMed
Graphical abstract
Abstract
Endocrine tumors are a heterogeneous cluster of malignancies that originate from cells that can secrete hormones. Examples include, but are not limited to, thyroid cancer, adrenocortical carcinoma, and neuroendocrine tumors. Many endocrine tumors are relatively slow to proliferate, and as such, they often do not respond well to common antiproliferative chemotherapies. Therefore, increasing attention has been given to targeted therapies and immunotherapies in these diseases. However, in contrast to other cancers, many endocrine tumors are relatively rare, and as a result, less is understood about their biology, including specific targets for intervention. Our limited understanding of such tumors is in part due to a limitation in model systems that accurately recapitulate and enable mechanistic exploration of these tumors. While mouse models and 2D cell cultures exist for some endocrine tumors, these models often may not accurately model nuances of human endocrine tumors. Mice differ from human endocrine physiology and 2D cell cultures fail to recapitulate the heterogeneity and 3D architectures of in vivo tumors. To complement these traditional cancer models, bioengineered 3D tumor models, such as organoids and tumor-on-a-chip systems, have advanced rapidly in the past decade. However, these technologies have only recently been applied to most endocrine tumors. In this review we provide descriptions of these platforms, focusing on thyroid, adrenal, and neuroendocrine tumors and how they have been and are being applied in the context of endocrine tumors.
Search for other papers by Darren Cowzer in
Google Scholar
PubMed
Search for other papers by Ronak H Shah in
Google Scholar
PubMed
Search for other papers by Joanne F Chou in
Google Scholar
PubMed
Search for other papers by Ritika Kundra in
Google Scholar
PubMed
Search for other papers by Sippy Punn in
Google Scholar
PubMed
Search for other papers by Laura Fiedler in
Google Scholar
PubMed
Search for other papers by April DeMore in
Google Scholar
PubMed
Search for other papers by Marinela Capanu in
Google Scholar
PubMed
Department of Pathology and laboratory medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
Search for other papers by Michael F Berger in
Google Scholar
PubMed
Weill Medical College of Cornell University, New York, New York, USA
Search for other papers by Diane Reidy-Lagunes in
Google Scholar
PubMed
Weill Medical College of Cornell University, New York, New York, USA
Search for other papers by Nitya Raj in
Google Scholar
PubMed
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma–tissue concordance of detected alterations, and clinical utility of cfDNA. Patients with metastatic PanNENs underwent cfDNA collection in routine practice. Next-generation sequencing (NGS) of cfDNA and matched tissue when available was performed. Clinical actionability of variants was annotated by OncoKB. Thirty-two cfDNA samples were analyzed from 25 patients, the majority who had well-differentiated intermediate grade disease (13/25; 52%). Genomic alterations were detected in 68% of patients and in 66% of all cfDNA samples. The most frequently altered genes were DAXX (28%), TSC2 (24%), MEN1 (24%), ARID1B (20%), ARID1A (12%), and ATRX (12%). Twenty-three out of 25 (92%) patients underwent tumor tissue NGS. Tissue–plasma concordance for select genes was as follows:DAXX (95.7%), ARID1A (91.1%), ATRX (87%), TSC2 (82.6%), MEN1 (69.6%). Potentially actionable alterations were identified in cfDNA of 8 patients, including TSC2 (4; level 3b), ATM (1; level 3b), ARID1A (2; level 4), and KRAS (1; level 4). An ETV6:NTRK fusion detected in tumor tissue was treated with larotrectinib; at progression, sequencing of cfDNA identified an NTRK3 G623R alteration as the acquired mechanism of resistance; the patient enrolled in a clinical trial of a second-generation TRK inhibitor with clinical benefit. In metastatic PanNENs, cfDNA-based NGS identified tumor-associated mutations in 66% of plasma samples with a high level of plasma-tissue agreement in PanNEN-associated genes. Clonal evolution, actionable alterations, and resistance mechanisms were detected through circulating cfDNA genotyping.
Search for other papers by Xiangqian Zheng in
Google Scholar
PubMed
Search for other papers by Meiyu Fang in
Google Scholar
PubMed
Search for other papers by Yun Fan in
Google Scholar
PubMed
Search for other papers by Yuping Sun in
Google Scholar
PubMed
Search for other papers by Meili Sun in
Google Scholar
PubMed
Search for other papers by Ankui Yang in
Google Scholar
PubMed
Search for other papers by Bin Zhang in
Google Scholar
PubMed
Search for other papers by Qinjiang Liu in
Google Scholar
PubMed
Search for other papers by Hui Liu in
Google Scholar
PubMed
Search for other papers by Xiaohong Zhou in
Google Scholar
PubMed
Search for other papers by Tao Huang in
Google Scholar
PubMed
Search for other papers by Jianwu Qin in
Google Scholar
PubMed
Search for other papers by Zhaohui Wang in
Google Scholar
PubMed
Search for other papers by Mengmeng Qin in
Google Scholar
PubMed
Search for other papers by Zhenwei Shen in
Google Scholar
PubMed
Search for other papers by Sheng Yao in
Google Scholar
PubMed
Search for other papers by Jason Yang in
Google Scholar
PubMed
Search for other papers by Yu Wang in
Google Scholar
PubMed
Department of Breast and Thyroid Surgery, Tianjin Union Medical Center, Tianjin, Tianjin, China
Search for other papers by Ming Gao in
Google Scholar
PubMed
Pralsetinib has demonstrated efficacious activity in various solid tumors, including medullary thyroid cancer (MTC), as observed in the phase 1/2 global ARROW study (BLU-667-1101; NCT03037385). We evaluated the safety and efficacy of pralsetinib in Chinese patients with advanced RET-mutant MTC. In the extension cohort of ARROW, adult patients with advanced MTC, who had not received systemic therapy (except for cytotoxic chemotherapy), were treated with pralsetinib (400 mg once daily, orally). The primary endpoints were blinded independent central-reviewed (BICR) objective response rate (ORR) and safety. Between October 9, 2019, and April 29, 2020, 34 patients were enrolled at 12 centers across China. Among them, 28 patients tested positive for RET mutations in the central laboratory, and 26 of these, with measurable disease at baseline per BICR, were included in the analysis set for tumor response. As of April 12, 2021 (data cutoff), the ORR was 73.1% (95% CI: 52.2–88.4), and the median duration of response was not reached. The most common (≥15%) grade ≥3 treatment-related adverse events (TRAEs) in the 28 patients with RET-mutant MTC were neutrophil count decreased (8/28, 28.6%), blood creatine phosphokinase increased (6/28, 21.4%), and lymphocyte count decreased (5/28, 17.9%). Serious TRAEs were reported by six patients (21.4%), with the most common event being pneumonia (3/28, 10.7%). No patient discontinued treatment or died from pralsetinib-related adverse events. Pralsetinib demonstrated broad, deep, and durable efficacy, as well as a manageable and acceptable safety profile in Chinese patients with advanced RET-mutant MTC.
Search for other papers by Anna Angelousi in
Google Scholar
PubMed
Search for other papers by Ploutarchos Tzoulis in
Google Scholar
PubMed
Search for other papers by Marina Tsoli in
Google Scholar
PubMed
Search for other papers by Eleftherios Chatzellis in
Google Scholar
PubMed
Search for other papers by Anna Koumarianou in
Google Scholar
PubMed
Search for other papers by Gregory Kaltsas in
Google Scholar
PubMed
Immunotherapy has revolutionised the treatment of oncological patients, but its application in various endocrine tumours is rather limited and is mainly used when conventional therapies have failed. Immune checkpoint inhibitors (ICIs) have been employed in progressive adrenocortical carcinoma, primarily utilizing the anti-PD-L1 agent pembrolizumab, obtaining overall response rates ranging between 14% and 23%. In contrast, the response rate in phaeochromocytoma/paraganglioma was substantially less at 9%, considering the small number of patients treated. Similarly, the response rate in advanced differentiated thyroid carcinomas treated with pembrolizumab was also low at 9%, although the combination of ICIs with tyrosine kinase inhibitors showed higher efficacy. Low response rates to ICIs have also been observed in progressive medullary thyroid cancer, except in tumours with a high mutation burden (TMB). Pembrolizumab or spartalizumab can be utilized in patients with high TMB anaplastic thyroid cancer, obtaining better response rates, particularly in patients with high PD-L1 expression. Immunotherapy has also been used in a few cases of parathyroid carcinoma, showing limited antitumour effect. Pituitary carcinomas may exhibit a more favourable response to ICIs compared to aggressive pituitary tumours, particularly corticotroph tumours. Patients with advanced neuroendocrine tumours achieve an overall response rate of 15%, which varies according to the primary tumour site of origin, degree of differentiation, and therapeutic regimen utilised. Future research is needed to evaluate the potential role of immunohistochemical biomarkers, such as programmed death 1/programmed death ligand 1 and TMB, as predictors for the response to immunotherapy. Furthermore, randomised prospective studies could provide more robust data on the efficacy and side effects of ICIs.
Department of Urology IEO European Institute of Oncology, IRCCS, Via Ripamonti, Milan, Italy
Università degli Studi di Milano, Milan, Italy
Search for other papers by Letizia Maria Ippolita Jannello in
Google Scholar
PubMed
Department of Neurosciences, Science of Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy
Search for other papers by Simone Morra in
Google Scholar
PubMed
Department of Urology, Medical University of Graz, Graz, Austria
Search for other papers by Lukas Scheipner in
Google Scholar
PubMed
Università degli Studi di Milano, Milan, Italy
Department of Urology, IRCCS Policlinico San Donato, Milan, Italy
Search for other papers by Andrea Baudo in
Google Scholar
PubMed
Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany
Search for other papers by Carolin Siech in
Google Scholar
PubMed
Division of Experimental Oncology/Unit of Urology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy
Search for other papers by Mario de Angelis in
Google Scholar
PubMed
Search for other papers by Nawar Touma in
Google Scholar
PubMed
Search for other papers by Zhe Tian in
Google Scholar
PubMed
Search for other papers by Jordan A Goyal in
Google Scholar
PubMed
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy
Search for other papers by Stefano Luzzago in
Google Scholar
PubMed
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy
Search for other papers by Francesco A Mistretta in
Google Scholar
PubMed
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy
Search for other papers by Mattia Luca Piccinelli in
Google Scholar
PubMed
Search for other papers by Fred Saad in
Google Scholar
PubMed
Search for other papers by Felix K H Chun in
Google Scholar
PubMed
Search for other papers by Alberto Briganti in
Google Scholar
PubMed
Search for other papers by Sascha Ahyai in
Google Scholar
PubMed
Department of Urology, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milan, Italy
Search for other papers by Luca Carmignani in
Google Scholar
PubMed
Search for other papers by Nicola Longo in
Google Scholar
PubMed
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy
Search for other papers by Ottavio de Cobelli in
Google Scholar
PubMed
Department of Oncology and Haemato-Oncology, Università degli Studi di Milano, Milan, Italy
Search for other papers by Gennaro Musi in
Google Scholar
PubMed
Search for other papers by Pierre I Karakiewicz in
Google Scholar
PubMed
We developed a novel contemporary population-based model for predicting cancer-specific survival (CSS) in adrenocortical carcinoma (ACC) patients and compared it with the established 8th edition of the American Joint Committee on Cancer staging system (AJCC). Within the Surveillance, Epidemiology, and End Results database (2004–2020), we identified 1056 ACC patients. Univariable Cox regression model addressed CSS. Harrell’s concordance index (C-index) quantified accuracy after 2000 bootstrap resamples for internal validation. The multivariable Cox regression model included the most informative, statistically significant predictors. Calibration and decision curve analyses (DCAs) tested the multivariable model as well as AJCC in head-to-head comparisons. Age at diagnosis (>60 vs ≤60 years), surgery, T, N, and M stages were included in the multivariable model. Multivariable model C-index for 3-year CSS prediction was 0.795 vs 0.757 for AJCC. Multivariable model outperformed AJCC in DCAs for the majority of possible CSS-predicted values. Both models exhibited similar calibration properties. Finally, the range of the multivariable model CSS predicted probabilities raged 0.02–75.3% versus only four single AJCC values, specifically 73.2% for stage I, 69.7% for stage II, 46.6% for stage III, and 15.5% for stage IV. The greatest benefit of the multivariable model-generated CSS probabilities applied to AJCC stage I and II patients. The multivariable model was more accurate than AJCC staging when CSS predictions represented the endpoint. Additionally, the multivariable model outperformed AJCC in DCAs. Finally, the AJCC appeared to lag behind the multivariable model when discrimination addressed AJCC stage I and II patients.
Search for other papers by Igryl S Cordero-Hernandez in
Google Scholar
PubMed
Search for other papers by Alicia C Ross in
Google Scholar
PubMed
Search for other papers by Arvind Dasari in
Google Scholar
PubMed
Search for other papers by Daniel M Halperin in
Google Scholar
PubMed
Search for other papers by Beth Chasen in
Google Scholar
PubMed
Search for other papers by James C Yao in
Google Scholar
PubMed
We observed that some patients with well-differentiated neuroendocrine tumors (NET) who received peptide receptor radionuclide therapy (PRRT) with Lutetium-177 (177Lu) DOTATATE developed rapid disease progression with biopsy-proven histologic transformation to neuroendocrine carcinoma (NEC), an outcome that has not been previously described. Therefore, we conducted a retrospective review of all patients with well-differentiated G1-G2 NET who received at least one cycle of PRRT with (177Lu) DOTATATE at our center from January 2019 to December 2020. Among 152 patients, we identified 7 patients whose NET transformed to NEC. Median time from start of PRRT to transformation was 8.2 months (range: 2.6–14.4 months). All patients whose tumors underwent transformation had pancreatic tail as the primary site and had prior chemotherapy with temozolomide. No differences in the incidence of transformation were observed according to gender, race, original tumor grade, or number of prior therapies. Six patients received treatment with platinum and etoposide after transformation with two patients having partial response as best response. All patients with transformation died from progressive disease with median overall survival (OS) after transformation of 3.3 months (95% CI 2.1–4.4). Molecular testing of transformed NEC identified mutation(s) in TP53 and/or ATM in all cases. Transformation of NET to NEC following PRRT is associated with aggressive course and dismal prognosis. Patients with pancreatic tail as the primary site who had prior therapy with temozolomide may be at a higher risk. Further investigation is necessary to determine the best treatment sequence in this patient population.
Search for other papers by Philipp Melhorn in
Google Scholar
PubMed
Search for other papers by Peter Mazal in
Google Scholar
PubMed
Search for other papers by Ladislaia Wolff in
Google Scholar
PubMed
Search for other papers by Petar Popov in
Google Scholar
PubMed
Search for other papers by Elisabeth Kretschmer-Chott in
Google Scholar
PubMed
Search for other papers by Alexander Haug in
Google Scholar
PubMed
Weill Cornell Medical College, Cornell University, New York, New York, USA
Search for other papers by Marius E Mayerhoefer in
Google Scholar
PubMed
Search for other papers by Markus Raderer in
Google Scholar
PubMed
Search for other papers by Barbara Kiesewetter in
Google Scholar
PubMed
The chemotherapy regimen capecitabine/temozolomide (CAPTEM) is routinely used in neuroendocrine tumors (NET), with antitumor activity particularly demonstrated in pancreatic or high-grade neuroendocrine neoplasms (NEN). However, different dosing regimens are used, and the optimal schedule remains to be defined. This single-center retrospective analysis assessed the efficacy and safety of CAPTEM in patients with NEN using a schedule starting both compounds simultaneously (temozolomide on days 1–5 and capecitabine on days 1–14 of a 28-day cycle) rather than sequentially. The primary parameters of interest were response rates, progression-free survival (PFS), and toxicities following this treatment regimen, hereinafter referred to as TEMCAP. The study population comprised 40 patients, half of whom (n = 20) had pancreatic NEN, and 9 patients (22.5%) had pulmonary or thymic NETs. The most common histology was NET G3 (n = 15, 37.5%), and 8 patients (20.0%) had a neuroendocrine carcinoma (NEC). Most patients (77.5%) had at least one prior systemic therapy, and 16 patients (40.0%) prior chemotherapy. The median number of TEMCAP cycles was 6 (range 1–16). Median PFS for the highly heterogeneous population was 13.3 months, while the median overall survival was 31.9 months. In total, 14/36 patients (38.9%) exhibited a partial response, and the disease control rate was 75.0%. The safety profile of TEMCAP (at a below-target mean temozolomide dose of 118.85 mg/m2) in our cohort was remarkably good with no toxicities of grade 3 or 4. Taken together, the results of this analysis further support the use of temozolomide/capecitabine in NEN and prompt further assessment of our modified TEMCAP schedule.
Search for other papers by Luming Wu in
Google Scholar
PubMed
Search for other papers by Jing Xie in
Google Scholar
PubMed
Search for other papers by Yan Qi in
Google Scholar
PubMed
Search for other papers by Tingwei Su in
Google Scholar
PubMed
Search for other papers by Lei Jiang in
Google Scholar
PubMed
Search for other papers by Weiwei Zhou in
Google Scholar
PubMed
Search for other papers by Yiran Jiang in
Google Scholar
PubMed
Search for other papers by Cui Zhang in
Google Scholar
PubMed
Search for other papers by Xu Zhong in
Google Scholar
PubMed
Search for other papers by Yanan Cao in
Google Scholar
PubMed
Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China
Search for other papers by Weiqing Wang in
Google Scholar
PubMed
Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Chile
Search for other papers by Verónica A Bahamondes Lorca in
Google Scholar
PubMed
Department of Chemistry and Biochemistry, Ohio University, Athens, Ohio, USA
Search for other papers by Shiyong Wu in
Google Scholar
PubMed
Radiotherapy is one of the major options currently for cancer treatment. Radiotherapy causes cellular damage inducing cell death, which is expected to be selective for tumor cells. However, side effects that alter the surrounding normal tissue are often hard to be avoided. When radiation involves the hypothalamic–pituitary axis, growth hormone deficiency (GHD) is frequently induced, causing developmental and metabolic-related diseases in childhood cancer survivors. Growth hormone (GH) replacement therapy has been used for these patients and has been shown to be safe in general. However, there are some debating for its long-term safety due to the known roles of GH in inducing cell growth, which could be related to cancer recurrence. In addition, studies have shown that GH is involved in the development of resistance to chemotherapy and radiotherapy through various mechanisms. In this review, we will first discuss the effects of GHD induced after radiotherapy and the safety of the GH replacement treatment. Then, we will discuss the role of the GH–IGF-1 axis in radioresistance via a mechanism of improving DNA repair.